Trajectories of Change in Tourette Syndrome
Launched by UNIVERSITY OF MINNESOTA · Nov 5, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, titled "Trajectories of Change in Tourette Syndrome," is focused on understanding how symptoms of Tourette Syndrome and tic disorders change over time, especially during a behavioral treatment. The study aims to recruit 30 young people aged 12 to 17 who have had chronic tics for at least a year. Eligible participants will need to have moderate tic severity and should be fluent in English. The study will not include individuals with certain mental health conditions, low IQ, or recent substance abuse.
Participants in this trial can expect to go through three phases over 16 weeks: a pre-intervention phase lasting four weeks, an eight-week intervention phase, and a four-week post-intervention phase. Throughout this time, researchers will gather information about their tic symptoms through traditional assessments, daily check-ins via smartphone (which will occur four times a day), and data from wearable devices. This study seeks to find tailored treatments that can improve the lives of those with Tourette Syndrome by understanding how their symptoms change in response to different factors and interventions.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Presence of chronic motor and/or vocal tics, defined as tics for at least 1 year without a tic-free period of more than 3 consecutive months. Tics must not be due to a medical condition or the direct physiological effects of a substance.
- • 2. At least moderate tic severity, defined as a Yale Global Tic Severity Scale44 total score ≥14 (≥9 for those with motor or vocal tics only).
- • 3. Participants must be fluent in English to ensure comprehension of study measures and instructions.
- Exclusion Criteria:
- • 1. Previous diagnosis of psychosis or cognitive disability,
- • 2. IQ \< 80,
- • 3. Substance abuse or dependence within the past year.
- • 4. Current suicidal intent.
- • 5. Changes in medication in the previous 4 weeks.
About University Of Minnesota
The University of Minnesota is a leading academic institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a focus on interdisciplinary collaboration, the university leverages its extensive resources and expertise to conduct cutting-edge studies aimed at improving patient outcomes and addressing critical health challenges. Its robust clinical trial program emphasizes ethical standards, patient safety, and scientific rigor, contributing to the development of novel therapies and interventions that enhance medical practice and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Minneapolis, Minnesota, United States
Patients applied
Trial Officials
Brianna Wellen
Principal Investigator
University of Minnesota
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported